Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Contract Research Firm CMIC Joins Pharma Market With Orphan Drug, With More On The Way

This article was originally published in PharmAsia News

Executive Summary

Novartis and Novo Nordisk receive first global approvals for compounds in Japan in recent slate of approvals, along with a wave of government-subsidized orphan drugs.

You may also be interested in...



Degludec Advisory Committee Is Another De Facto Delay For Novo

FDA’s advisory committee meeting on Nov. 8 falls just after the already-extended user fee date for Novo Nordisk’s long-acting insulin degludec and degludec/insulin aspart.

FCPA In The China Framework Warrants Special Attention

The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?

Astellas Regains Japan Losses With Xtandi Expansion

Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC079601

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel